Table 1. Engraftment and severe GvHD... | American Society of Hematology

Table 1.

Engraftment and severe GvHD incidence

	PBLs	aCD3-TK⁺	baCD3/CD28-TK⁺
Engraftment
Average human chimerism, % (range)	6.7 (2.0-21.1)	1.8 (0.1-4.6)	5.8 (0.1-15.3)‡
CD4⁺/CD8⁺	2.0 ± 0.7	0.7 ± 0.2	1.0 ± 0.5
CD28⁺CD27⁺, %	79.2 ± 7.6	70.1 ± 11.5	74.6 ± 9.8
Average CD28^–CD27⁺, %	15.8 ± 2.1	18.6 ± 2.7	20.2 ± 3.2
Average CD45RA^–CCR7⁺, %	67.5 ± 11.7	1.1 ± 0.7	58.9 ± 7.3‡
Average CD45RA^–CCR7^–, %	15.4 ± 4.8	87.0 ± 9.2	25.2 ± 5.4‡
Severe GvHD
Incidence^*	25/25	3/27	15/27‡
Latency, d†	15.9 ± 4.1	33.5 ± 6.4	30.2 ± 8.2
Average human chimerism, % (range)	33.1 (16.5-59.9)	19.7 (10.3-29.9)	26.9 (17.5-35.2)
Average clinical index, arbitrary units	5.5 ± 0.9	4.3 ± 0.6	4.8 ± 1.0

	PBLs	aCD3-TK⁺	baCD3/CD28-TK⁺
Engraftment
Average human chimerism, % (range)	6.7 (2.0-21.1)	1.8 (0.1-4.6)	5.8 (0.1-15.3)‡
CD4⁺/CD8⁺	2.0 ± 0.7	0.7 ± 0.2	1.0 ± 0.5
CD28⁺CD27⁺, %	79.2 ± 7.6	70.1 ± 11.5	74.6 ± 9.8
Average CD28^–CD27⁺, %	15.8 ± 2.1	18.6 ± 2.7	20.2 ± 3.2
Average CD45RA^–CCR7⁺, %	67.5 ± 11.7	1.1 ± 0.7	58.9 ± 7.3‡
Average CD45RA^–CCR7^–, %	15.4 ± 4.8	87.0 ± 9.2	25.2 ± 5.4‡
Severe GvHD
Incidence^*	25/25	3/27	15/27‡
Latency, d†	15.9 ± 4.1	33.5 ± 6.4	30.2 ± 8.2
Average human chimerism, % (range)	33.1 (16.5-59.9)	19.7 (10.3-29.9)	26.9 (17.5-35.2)
Average clinical index, arbitrary units	5.5 ± 0.9	4.3 ± 0.6	4.8 ± 1.0

Engraftment was determined 1 week after infusion. Where applicable, values are ± SD.

Defined as weight loss greater than 5% and human chimerism greater than 10%

Calculated as time from infusion to severe GvHD

P < .01 for comparison with mice infused with aCD3-TK⁺ lymphocytes